Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00381888 · OUTCOME

Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Week 4

What was measured

This is a count of patients who did not have a clot (thromboembolism) occur during the 4 weeks of study - attributed to the use of Fondaparinux (study dry). Prophylaxis is a measure taken for the prevention of a disease or condition.

Analysis population: These patients completed the study and are considered evaluable for this outcome measure.

Groups in this outcome

Fondaparinux Patients Who Completed Study

This number includes all patients that completed 4 weeks of the study and were treated with 2.5 mg of Fondaparinux on days 1-28.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fondaparinux Patients Who Completed Study27

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Fondaparinux Patients Who Completed Study27Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        27
denoms
  1. counts
    1. group Id
      OG000
      value
      27
    units
    Participants
description
This is a count of patients who did not have a clot (thromboembolism) occur during the 4 weeks of study - attributed to the use of Fondaparinux (study dry). Prophylaxis is a measure taken for the prevention of a disease or condition.
groups
  1. description
    This number includes all patients that completed 4 weeks of the study and were treated with 2.5 mg of Fondaparinux on days 1-28.
    id
    OG000
    title
    Fondaparinux Patients Who Completed Study
param Type
NUMBER
population Description
These patients completed the study and are considered evaluable for this outcome measure.
reporting Status
POSTED
time Frame
Week 4
title
Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice